Samuel J. Klempner, MD, on Advanced Gastric/GEJ Cancer: Zolbetuximab Plus mFOLFOX6 and Nivolumab

January 08, 2026 By The ASCO Post Staff

Samuel J. Klempner, MD, of Massachusetts General Hospital, discusses results from the phase II ILUSTRO trial, which evaluated the combination of the anti-CLDN18.2 antibody zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive; HER2-negative; locally advanced, unresectable, or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma (Abstract LBA284). 

Related Content